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Diagnosis acute GVHD chronic GVHD Previous therapy
FA Skin, gut Skin, gut, eye ,liver CTC/ CSA/ basiliximab
FA Gut, stomach Mouth, liver CTC/ CSA/ basiliximab
MDS skin skin, mouth CTC/ CSA/ AZA
MDS (second
ECP cycle)
skin CTC/ CSA/ AZA
AAS skin Skin, liver, lung CTC/ CSA/ basiliximab
FA Skin, gut, liver Skin, gut, liver CTC/ CSA /basiliximab/
MMF/Tacrolimus
ALL Skin Mouth, skin, liver, eye CTC/CSA
CML skin, liver Skin, eye, stomach,
liver, mouth, fascia
CTC/ CSA/ MMF
BDA Skin, eye,
mouth
CTC/ CSA/ basiliximab
SCID skin Skin, gut, liver CTC/ CSA/ basiliximab/
AZA/ Tacrolimus
IFN gama
deficiency
Skin, eye,
mouth
CTC/ CSA/ basiliximab
CML Skin, eye Skin, lung, eye, mouth CTC/ CSA
FA Skin, eye Skin, fascia, eye CTC/ CSA/
S312 Poster Session IIWe retrospectively analysed 22 patients (10 females e 12 males)
who received HSCT between 01/1999 and 01/2009 and devel-
oped as complicattion chronic GVHD steroid refractory or de-
pendent and who received MMF as second line therapy.
Diagnosis: Fanconi Anemia (8); Chronic Myeloid Leukemia(5);
Others(9). Cell source was marrow in 16, pheripheral blood
(pb) in 3, and cord blood in 3 patients. Eight patients received
HSCT from related and 14 from unrelated donors. Immunopro-
phylaxis was: CSA e methotrexate (MTX) (15); CSA e CTC(2);
CSA, MTX and methylprednisolone (5). All patients had exten-
sive chronic GVHD. As we reclassified them according to the
NIH consensus criteria, 15 (68%) of them had severe disease
and 7(39%) had moderate disease. Thirteen (59%) had progres-
sive, 8 (36%) had ‘‘de novo’’ and 1 (5%) quiescent GVHD. Liver,
oral mucosa and skin were the sites most frequently envolved.
Nine patients had more than 3 organs involved, 6 were using ste-
roids at the time of diagnosis and 5 had thrombocytopenia lower
than 100.000/mm3. Overall response defined by improvement in
at least one organ or estabilization of GVHD was observed in 15
(68%) patients. Eleven patients (50%) stopped steroids after a me-
dian of 16.5 months. Eight patients (36%) stopped all immunesu-
pression in a median time of 43 months. Four patients died for
reasons related to their GVHD and 3 others received another
drug for failure with MMF. We did not observe grade 2-4 toxicity
leading to suspension of the drug.
In conclusion MMF was a safe drug as therapy for chronic steroid
dependent or refractory GVHD with an overall response of 68% in
this population. Prospective trials are necessary for a better evalua-
tion of the efficacy of this drug as second line therapy for chronic
graft-versus-host-disease.basiliximab/ PUVA/
Tacrolimus/ MMF
CML skin Skin, mouth, eye, liver CTC/ CSA/ thalidomide/
AZA/ MMF
JMML Skin,
gastrointestinal
tract
CTC/ CSA/ basiliximab
CML Skin, liver Mouth, eye, liver CTC/ CSA/ Tacrolimus
AF: Fanconi anemia, SMD:myelodysplastic syndrome; AAS: severe aplas-
tic anemia; LLA: acute lymphoblastic leukemia LMC: chronic myeloid
leukemia, ABD: Diamond-Blackfan anemia, SCID: severe combined im-
munodeficiency, JMML: juvenile chronic myelomonocytic leukemia,
AZA: azathioprine; MMF: mycophenolate mofetil.420
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CHRONIC GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC STEM
CELL TRANSPLANTATION
Franco, V., Funke, V.A.M., Nunes, E.C., Setubal, D.C., Medeiros, L.,
Michels, M., Bonamin, C., Nabhan, S., Ribeiro, L., Morando, J.,
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Parana, Brazil
Introduction:Graft- versus-host disease (GVHD) after hematopoi-
etic stem cell transplantation (HSCT) is associated with high mor-
bidity and mortality rates. Corticosteroids and calcineurin
inhibitors are the first line treatment of GVHD.There are many sec-
ond line therapies with few controlled studies. Extracorporeal Pho-
topheresis (ECP) is an immunomodulatory treatment which has
recently been proof as steroid sparing procedure (Flowers et al,
Blood. 2008 Oct 1;112(7):2667-74)
Objective:We describe our experience at the Hospital de Clınicas
from the Federal University of Parana- Brazil, with ECP in pa-
tients with steroid refractory or dependent acute or chronic
GVHD.
Patients andMethods:We reviewed between Februray 2002 and
June, 2009, the data of 19 patients who received allogeneic he-
matopoietic stem cell transplantation (HSCT) and developed
as complication acute and/or cronic GVHD refractory to corti-
costeroids and cyclosporine therapy and were then treated with
ECP (20 procedures: one patient had been submitted twice).
Four patients were excluded because they had received less
than six sessions; fifteen patients were evaluated (female:13
male:2). The mean age at HSCT was 11 years (range 3 to 49).
Partial response was defined by an improvement in at least one
involved organ and complete response as resolution of all symp-
toms of GVHD. The clinical characteristics of these patients are
in Table 1.
Results:Median overall survival afterHSCTwas 2 years (range 3 m-
13y). Five patients were submitted to ECP due to acute GVHD and
13 due to chronic GVHD (2 patients had overlap syndrom
GVHD.Three of 5 patients with acute GVHD (60%) had total re-
sponse, 1 (20%) partial response and 1 (20%) had no response.
Nine of 13 patients with chronic GVHD (70%) had partial response,
2 (15%) total response and 2 (15%) had no response. Ten patients(67%) reduced the dosage of corticosteroid to less than 0,5 mg/kg/d.
There were no severe adverse effects related to ECP.
Conclusion: ECP is an effective alternative in the treatment of
GVHD in this study, with no severe adverse effects observed. The
procedure allowed reduction of corticosteroids in 67% of our pa-
tients. Prospective trials are necessary for a more precise evaluation
of this procedure in GVHD therapy.421
SOLUBLE HUMAN LEUKOCYTE ANTIGEN G (SHLA-G) IN HEMATOPOIETIC
CELL TRANSPLANTATION IS ASSOCIATED WITH SEVERAL CLINICAL
COMPLICATIONS AFTER TRANSPLANT
Waterhouse, M., Duque-Afonso, J., Samek, E., Bertz, H., Finke, J.
Freiburg University Medical Center, Freiburg, Baden Wuettemberg,
Germany
HLA-G is a non classical class I HLA molecule with low level of
polymorphisms and with 7 isoforms, 4 are membrane bound and 3
are soluble. Another differential characteristic is it is tissue restricted
and have been described in adult thymic medulla, cornea, pancreatic
islet and endothelial cell precursors. Several immune modulatory
functions have been attributed to this molecule such as the interac-
tion between B, T,NK and antigen presenting cells. Due to their im-
munomodulatory properties we investigated the possible role of
soluble HLA-G (sHLA-G) in the allogeneic hematopoietic cell
transplantation (HCT) setting. A cohort of 37 patients, who under-
went HCT, were studied, 13 patients had acute myeloid leukemia, 8
patients had myelodisplastic syndromes (preleukemia disease) while
the rest of the patients had non myeloid malignancies. Twenty eight
patients received reduce intensity conditioning regimen, while the
rest of the patients received myeloablative conditioning treatment.
Plasma samples from all patients were obtained before the condition-
ing regimen and after transplant at different timepoints. Soluble
HLA-G concentration was measured in duplicates of plasmas by
a specific enzyme-linked immunosorbent assay (ELISA) using the
MEMG/9 as the capture antibody. Pre transplant variables were
age, gender, disease, type of transplant (related, unrelated), infused
marrow cell dose and donor gender. Post transplantation variables
